Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple

Translated title of the contribution: Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis

Inmaculada Tasset, Eduardo Agüera, Félix Gascón, Ana I. Giraldo, Manuel Salcedo, Antonio H. Cruz, Fernando Sánchez, Isaac Túnez

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction. The sensitivity of the central nervous system to oxidative damage and its relationship with inflammatory response are well known. Recent studies have shown that oxidative stress is present in the establishment and development of multiple sclerosis (MS). One of the most recent treatments in this process is natalizumab, a monoclonal antibody. Aim. To evaluate whether the therapeutic effect of natalizumab is associated with the severity of the disease and the oxidative damage. Patients and methods. Researchers recruited twenty patients with relapsing-remitting MS (RRMS) undergoing therapy with natalizumab and distributed, according to the Expanded Disability Status Scale (EDSS), in two groups: RRMS-1 (EDSS < 5) and RRMS-2 (EDSS ≥ 5). Blood samples were taken for an oxidative profile study. Results. Data showed a decrease in carbonylated proteins following treatment with natalizumab. The reduction in oxidative damage rated as protein oxidation is significant between the previous (baseline) situation of the patient and after 14 months' treatment. The most significant decrease coincided with the patients with the highest levels of severity in the process. Although it has not been possible to establish a correlation, the statistical significance is higher for patients in the RRMS-2 group treated with natalizumab. The antioxidant systems, on the other hand, did not display any statistically significant changes. Conclusions. Natalizumab brings about a reduction in carbonylated protein levels.

Original languageSpanish
Pages (from-to)449-452
Number of pages4
JournalRevista de Neurologia
Volume54
Issue number8
StatePublished - 2012
Externally publishedYes

Fingerprint

Multiple Sclerosis
Proteins
Relapsing-Remitting Multiple Sclerosis
Therapeutic Uses
Therapeutics
Natalizumab
Oxidative Stress
Central Nervous System
Antioxidants
Monoclonal Antibodies
Research Personnel

Keywords

  • Antioxidant system
  • Carbonylated proteins
  • Multiple sclerosis
  • Natalizumab
  • Oxidative stress
  • Peripheral bio-markers

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Tasset, I., Agüera, E., Gascón, F., Giraldo, A. I., Salcedo, M., Cruz, A. H., ... Túnez, I. (2012). Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple. Revista de Neurologia, 54(8), 449-452.

Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple. / Tasset, Inmaculada; Agüera, Eduardo; Gascón, Félix; Giraldo, Ana I.; Salcedo, Manuel; Cruz, Antonio H.; Sánchez, Fernando; Túnez, Isaac.

In: Revista de Neurologia, Vol. 54, No. 8, 2012, p. 449-452.

Research output: Contribution to journalArticle

Tasset, I, Agüera, E, Gascón, F, Giraldo, AI, Salcedo, M, Cruz, AH, Sánchez, F & Túnez, I 2012, 'Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple', Revista de Neurologia, vol. 54, no. 8, pp. 449-452.
Tasset, Inmaculada ; Agüera, Eduardo ; Gascón, Félix ; Giraldo, Ana I. ; Salcedo, Manuel ; Cruz, Antonio H. ; Sánchez, Fernando ; Túnez, Isaac. / Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple. In: Revista de Neurologia. 2012 ; Vol. 54, No. 8. pp. 449-452.
@article{90132be965d04ede82617391431dfb1d,
title = "Natalizumab y reducci{\'o}n de los niveles de prote{\'i}nas carboniladas en pacientes con esclerosis m{\'u}ltiple",
abstract = "Introduction. The sensitivity of the central nervous system to oxidative damage and its relationship with inflammatory response are well known. Recent studies have shown that oxidative stress is present in the establishment and development of multiple sclerosis (MS). One of the most recent treatments in this process is natalizumab, a monoclonal antibody. Aim. To evaluate whether the therapeutic effect of natalizumab is associated with the severity of the disease and the oxidative damage. Patients and methods. Researchers recruited twenty patients with relapsing-remitting MS (RRMS) undergoing therapy with natalizumab and distributed, according to the Expanded Disability Status Scale (EDSS), in two groups: RRMS-1 (EDSS < 5) and RRMS-2 (EDSS ≥ 5). Blood samples were taken for an oxidative profile study. Results. Data showed a decrease in carbonylated proteins following treatment with natalizumab. The reduction in oxidative damage rated as protein oxidation is significant between the previous (baseline) situation of the patient and after 14 months' treatment. The most significant decrease coincided with the patients with the highest levels of severity in the process. Although it has not been possible to establish a correlation, the statistical significance is higher for patients in the RRMS-2 group treated with natalizumab. The antioxidant systems, on the other hand, did not display any statistically significant changes. Conclusions. Natalizumab brings about a reduction in carbonylated protein levels.",
keywords = "Antioxidant system, Carbonylated proteins, Multiple sclerosis, Natalizumab, Oxidative stress, Peripheral bio-markers",
author = "Inmaculada Tasset and Eduardo Ag{\"u}era and F{\'e}lix Gasc{\'o}n and Giraldo, {Ana I.} and Manuel Salcedo and Cruz, {Antonio H.} and Fernando S{\'a}nchez and Isaac T{\'u}nez",
year = "2012",
language = "Spanish",
volume = "54",
pages = "449--452",
journal = "Revista de Neurologia",
issn = "0210-0010",
publisher = "Revista de Neurologia",
number = "8",

}

TY - JOUR

T1 - Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple

AU - Tasset, Inmaculada

AU - Agüera, Eduardo

AU - Gascón, Félix

AU - Giraldo, Ana I.

AU - Salcedo, Manuel

AU - Cruz, Antonio H.

AU - Sánchez, Fernando

AU - Túnez, Isaac

PY - 2012

Y1 - 2012

N2 - Introduction. The sensitivity of the central nervous system to oxidative damage and its relationship with inflammatory response are well known. Recent studies have shown that oxidative stress is present in the establishment and development of multiple sclerosis (MS). One of the most recent treatments in this process is natalizumab, a monoclonal antibody. Aim. To evaluate whether the therapeutic effect of natalizumab is associated with the severity of the disease and the oxidative damage. Patients and methods. Researchers recruited twenty patients with relapsing-remitting MS (RRMS) undergoing therapy with natalizumab and distributed, according to the Expanded Disability Status Scale (EDSS), in two groups: RRMS-1 (EDSS < 5) and RRMS-2 (EDSS ≥ 5). Blood samples were taken for an oxidative profile study. Results. Data showed a decrease in carbonylated proteins following treatment with natalizumab. The reduction in oxidative damage rated as protein oxidation is significant between the previous (baseline) situation of the patient and after 14 months' treatment. The most significant decrease coincided with the patients with the highest levels of severity in the process. Although it has not been possible to establish a correlation, the statistical significance is higher for patients in the RRMS-2 group treated with natalizumab. The antioxidant systems, on the other hand, did not display any statistically significant changes. Conclusions. Natalizumab brings about a reduction in carbonylated protein levels.

AB - Introduction. The sensitivity of the central nervous system to oxidative damage and its relationship with inflammatory response are well known. Recent studies have shown that oxidative stress is present in the establishment and development of multiple sclerosis (MS). One of the most recent treatments in this process is natalizumab, a monoclonal antibody. Aim. To evaluate whether the therapeutic effect of natalizumab is associated with the severity of the disease and the oxidative damage. Patients and methods. Researchers recruited twenty patients with relapsing-remitting MS (RRMS) undergoing therapy with natalizumab and distributed, according to the Expanded Disability Status Scale (EDSS), in two groups: RRMS-1 (EDSS < 5) and RRMS-2 (EDSS ≥ 5). Blood samples were taken for an oxidative profile study. Results. Data showed a decrease in carbonylated proteins following treatment with natalizumab. The reduction in oxidative damage rated as protein oxidation is significant between the previous (baseline) situation of the patient and after 14 months' treatment. The most significant decrease coincided with the patients with the highest levels of severity in the process. Although it has not been possible to establish a correlation, the statistical significance is higher for patients in the RRMS-2 group treated with natalizumab. The antioxidant systems, on the other hand, did not display any statistically significant changes. Conclusions. Natalizumab brings about a reduction in carbonylated protein levels.

KW - Antioxidant system

KW - Carbonylated proteins

KW - Multiple sclerosis

KW - Natalizumab

KW - Oxidative stress

KW - Peripheral bio-markers

UR - http://www.scopus.com/inward/record.url?scp=84861304149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861304149&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 449

EP - 452

JO - Revista de Neurologia

JF - Revista de Neurologia

SN - 0210-0010

IS - 8

ER -